Login / Signup

gH625 Cell-Penetrating Peptide Promotes the Endosomal Escape of Nanovectorized siRNA in a Triple-Negative Breast Cancer Cell Line.

Sanaa Ben DjemaaKatel Hervé-AubertLaurie LajoieAnnarita FalangaStefania GaldieroSteven NedellecMartin SoucéEmilie MunnierIgor ChourpaStéphanie DavidEmilie Allard-Vannier
Published in: Biomacromolecules (2019)
The use of small interfering RNA (siRNA) to regulate oncogenes appears as a promising strategy in the context of cancer therapy, especially if they are vectorized by a smart delivery system. In this study, we investigated the cellular trafficking of a siRNA nanovector (called CS-MSN) functionalized with the cell-penetrating peptide gH625 in a triple-negative breast cancer model. With complementary techniques, we showed that siRNA nanovectors were internalized by both clathrin- and caveolae-mediated endocytosis. The presence of gH625 at the surface of the siRNA nanovector did not modify the entry pathway of CS-MSN, but it increased the amount of siRNA found inside the cells. Results suggested an escape of siRNA from endosomes, which is enhanced by the presence of the peptide gH625, whereas nanoparticles continued their trafficking into lysosomes. The efficiency of CS-MSN to inhibit the GFP in MDA-MB-231 cells was 1.7-fold higher than that of the nanovectors without gH625.
Keyphrases
  • cancer therapy
  • drug delivery
  • growth hormone
  • induced apoptosis
  • cell cycle arrest
  • hyaluronic acid
  • single cell
  • cell therapy
  • mesenchymal stem cells
  • nucleic acid